Aptevo Therapeutics Inc.
APVO
NSC
Sector: Healthcare
Industry: Biotechnology
1.64
USD
0.06
(3.80%)
Optionable: No Market Cap: 12 M 90-day average vol: 52,954
Previous close: 1.58 Open: 1.57 Bid: 1.58 Ask: 1.66
52 week range
1.51 7.20
Last updated: Thursday 8th June 2023
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
🎉 Exciting news! 🎉
You are invited to join our Discord Channel.
Interact, learn, and grow with experts in the markets!
Join our DiscordFinancials
APVO Income Statement
Annual
| Invalid date | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | |
|---|---|---|---|---|---|---|---|---|
| Amortization | -800000.0 | -800000.0 | -800000.0 | -800000.0 | -100000.0 | -6000.0 | ||
| Amortization of intangibles | -800000.0 | -800000.0 | 0.0 | 0.0 | ||||
| Basic EPS from continuing operations | 1.37 | |||||||
| Basic EPS total | 1.57 | |||||||
| Basic weighted shares outstanding | 1 M | 2 M | 2 M | 208359.0 | 3 M | 5 M | 5 M | |
| BasicDiscontinuousOperations | 0.2 | |||||||
| Cost of sales | -12 M | -5 M | -11 M | -20 M | ||||
| Depreciation | -1 M | -1 M | -2 M | -1 M | -1 M | -1 M | -900000.0 | |
| DepreciationAndAmortization | -1 M | -1 M | -2 M | -1 M | -1 M | -1 M | -900000.0 | |
| Diluted EPS total | 5.18 | 26.04 | -33.46 | 12.6 | 3.88 | 0.2 | 1.57 | |
| Diluted normalized net income/share | 1.37 | |||||||
| Diluted weighted shares outstanding | 5 M | |||||||
| DilutedDiscontinuousOperations | 0.2 | |||||||
| GainOnSaleOfBusiness | 14 M | |||||||
| GainOnSaleOfSecurity | 53 M | 4 M | 14 M | |||||
| GainsLossOnDisposalOfDiscontinuedOperations | 7 M | 40 M | 3 M | 13 M | 951000.0 | 1 M | ||
| GeneralAndAdministrativeExpense | -2 M | -2 M | -1 M | 16 M | 14 M | 15 M | 14 M | |
| Gross operating profit | -2 M | 10 M | 12 M | 12 M | 4 M | 12 M | 3 M | |
| ImpairmentOfCapitalAssets | 71 M | |||||||
| Income before tax | -140 M | -56 M | -54 M | -41 M | -31 M | -29 M | 7 M | |
| Income taxes | -20 M | -23 M | ||||||
| InterestExpenseNonOperating | -2000.0 | -1000.0 | ||||||
| MiscOtherSpecialCharges | -810000.0 | -2 M | -2 M | -2 M | -3 M | -8 M | 33 M | |
| Net income from total operations | -112 M | 7 M | -54 M | -40 M | -18 M | -28 M | 8 M | |
| NetIncomeCommonStockholders | -112 M | 7 M | -54 M | -40 M | -18 M | -28 M | 8 M | |
| NetIncomeContinuousOperations | -112 M | 7 M | -54 M | -40 M | -18 M | -28 M | 8 M | |
| NetIncomeDiscontinuousOperations | 7 M | 40 M | 3 M | 13 M | 951000.0 | 1 M | ||
| NetIncomeFromOtherGainsLosses | -2 M | -1 M | ||||||
| NetNonOperatingInterestIncomeExpense | 2000.0 | 1000.0 | ||||||
| Operating income | -68 M | -54 M | -52 M | -41 M | -27 M | -21 M | -29 M | |
| Operating income before depreciation (EBITDA) | -136 M | -53 M | -51 M | -39 M | -30 M | -28 M | 8 M | |
| OperatingExpense | 65 M | 64 M | 64 M | 41 M | 32 M | 34 M | 32 M | |
| OperatingRevenue | 10 M | 15 M | 23 M | 0.0 | 4 M | 12 M | 3 M | |
| Other income net | 810000.0 | 2 M | 2 M | -4 M | 3 M | 8 M | -33 M | |
| Other special charges | -2 M | |||||||
| OtherGandA | -2 M | -2 M | -1 M | 16 M | 14 M | 15 M | 14 M | |
| OtherOperatingExpenses | -2 M | -2 M | -2 M | -1 M | ||||
| RentAndLandingFees | -2 M | -2 M | 0.0 | 16 M | 14 M | 15 M | 14 M | |
| Research & development expense | 29 M | 29 M | 35 M | 25 M | 18 M | 19 M | 18 M | |
| ResearchExpense | 29 M | 29 M | 35 M | 25 M | 18 M | 19 M | 18 M | |
| SalariesAndWages | -4 M | -5 M | -2 M | -2 M | -1 M | -2 M | -2 M | |
| Selling Gen & administrative expense | 36 M | 35 M | 28 M | 16 M | 14 M | 15 M | 14 M | |
| SellingAndMarketingExpense | 36 M | 35 M | 28 M | 25 M | ||||
| SellingExpense | 36 M | 35 M | 28 M | 25 M | ||||
| Special income/charges | -71 M | 3 M | ||||||
| Total Income available for interest expense (EBIT) | -140 M | -56 M | -54 M | -41 M | -31 M | -29 M | 7 M | |
| Total common shares outstanding | 1 M | 2 M | 3 M | 3 M | 4 M | 5 M | 7 M | |
| Total net income | -112 M | 7 M | -54 M | -40 M | -18 M | -28 M | 8 M | |
| Total ordinary shares | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | |
| Total revenues | 10 M | 15 M | 23 M | 32 M | 4 M | 12 M | 3 M | |
| TotalExpenses | 53 M | 59 M | 52 M | 41 M | 32 M | 34 M | 32 M |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and starter sheets.
Get started today
Get started today